Here's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today
Shares of Aerie Pharmaceuticals (NASDAQ: AERI) jumped nearly 22% today after the company published an October investor presentation. The slide deck indicates that the ophthalmology, or eye-focused, pharma experienced a surge in the number of bottles of Rhopressa and Rocklatan shipped to pharmacies in the week ending Oct. 4.
Investors usually have to wait for prescription and bottle data sets from IQVIA to be published to gauge the trajectory of recent drug launches, but the latest numbers from IQVIA end on Sept. 27. Therefore, the surge in total product shipped is giving investors reason to cheer, especially after a surprisingly sluggish start.
As of 1:01 p.m. EDT, the stock had settled to a 17% gain.
Source Fool.com
